However, the recurrent somatic mutations of the tyrosine kinase receptor ALK identified in 8-10% of primary neuroblastoma tumours [4–8] and the emergence of ALK mutations at relapse mark ALK as an important novel drug target [9, 10]. This evidence concerns the gene ALK and neuroblastoma.